Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CAMBRIDGE, Mass., March 18, 2016 -- Mersana Therapeutics, Inc. today announced that it will present two posters, one of which includes data on its new preclinical immunoconjugate, at the 2016 American Association for Cancer Research (AACR) Annual Meeting being held April 16-20, 2016, at the Ernest N. Morial Convention Center in New Orleans, LA.
Details of the posters being presented are as follows:
Title: Optimization of Lead Antibody Selection for XMT-1522, a Novel, Highly Potent HER2-Targeted Antibody-Drug Conjugate
Abstract Number: 596
Poster Session: Therapeutic Antibodies, Section 27
Date: Sunday, April 17, 2016
Time: 1:00 p.m. – 5:00 p.m. CT
Presenter: Natasha Bodyak, Ph.D., M.B.A., Executive Director, Biology, Mersana Therapeutics
The abstract describes the discovery and characterization of the novel anti-HER2 antibody used in XMT-1522, a novel HER2-targeting therapy based on Mersana’s Fleximer® immunoconjugate technology that is highly active in low HER2-expressing tumors and is fully combinable with current HER2 antibody therapeutics.
Title: Discovery and Preclinical Development of a Highly Potent NaPi2b-Targeted Antibody-Drug Conjugate with Significant Activity in Patient-Derived Non-Small Cell Lung Cancer (NSCLC) Xenograft Models
Abstract Number: 1194
Poster Session: Growth Factor Receptors and Surface Antigens as Therapeutic Targets, Section 15
Date: Monday, April 18, 2016
Time: 8:00 a.m. – 12:00 p.m. CT
Presenter: Natasha Bodyak, Ph.D., M.B.A., Executive Director, Biology, Mersana Therapeutics
XMT-1536, Mersana’s second preclinical candidate, is a highly potent anti-NaPi2b immunoconjugate comprised of an average of 15 auristatin molecules conjugated to XMT-1535, a novel humanized anti-NaPi2b antibody, via the Dolaflexin™ antibody-drug conjugate platform.
For more information about the AACR Annual Meeting, visit http://www.aacr.org/.
About Mersana Therapeutics
Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.
Media Contact 6 Degrees Tony Plohoros [email protected] (908) 591-2839 Investors Contact Stern Investor Relations, Inc. Jesse Baumgartner [email protected] (212) 362-1200
